Work

A phase II study of anlotinib plus penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Results from ALTER-GO-020 trial.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.5527

Authors: Dengfeng Wang, Hong Liu, Lihong Chen, Mian He, Weidong Zhao, Yang Xiang, Guoqinq Wang, Guonan Zhang

Institutions: University of Electronic Science and Technology of China, Sichuan Cancer Hospital, Shaanxi Provincial People's Hospital, Shanxi Provincial People’s Hospital, The First Affiliated Hospital, Sun Yat-sen University, Anhui Provincial Hospital, Peking Union Medical College Hospital

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410813807

Cites:

Cited by: 1

Related to: 10